Apellis Pharmaceuticals to Present at Major Healthcare Conference
WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is excited to announce its participation in a significant upcoming healthcare conference. The company will be presenting at the Stifel 2025 Healthcare Conference, set to take place on a Wednesday at 2:40 p.m. ET. This event promises to gather leaders in the healthcare sector and provide a platform for innovative companies to highlight their advancements and discoveries.
Live Conference Presentation and Webcast Details
Apellis will share insights into its groundbreaking work during the conference. Attendees and interested parties can tune in via a live webcast that will be made available on the company's events page, specifically designed for investors and media. This format allows for wider access and real-time engagement for audiences unable to attend in person.
Replay Availability
For those who cannot join the live stream, a recording of the presentation will be accessible for approximately 90 days after the event, allowing interested parties to stay informed about the company’s latest developments and innovations in therapeutic solutions.
Leading the Way in Complement Science
Apellis Pharmaceuticals is at the forefront of complement science, striving to develop impactful therapies aimed at addressing some of the most complex diseases. The company has made significant strides over the years, notably introducing a new class of complement medicine—the first in 15 years. Their portfolio includes two groundbreaking C3-targeting medicines that are approved for treating four severe diseases.
Breakthrough Treatments
Among the noteworthy achievements of Apellis is the release of the first-ever therapy for geographic atrophy, a leading cause of blindness. This innovation represents a critical advancement for patients suffering from this debilitating condition. Additionally, Apellis has introduced the first treatment specifically for adolescents and adults over the age of 12 dealing with C3G and primary IC-MPGN, both of which are severe, rare kidney diseases. Such breakthroughs highlight the company's commitment to unlocking the potential of complement-targeting therapies across a variety of serious health conditions.
Future of Treatment and Research
The future looks promising for Apellis as they continue to explore the extensive applications of their research in complement sciences. The company is dedicated to not only developing effective treatments but also understanding how these therapies can be utilized for a broader spectrum of diseases. The implications of their work extend beyond just the present; they are tailoring their research to confront emerging healthcare challenges.
A Commitment to Patients
Integral to Apellis’ mission is their unwavering commitment to patients. They strive not just to provide therapies but to enhance the quality of life for individuals facing severe health challenges. By engaging with the community and allowing patient stories to influence research directions, Apellis fosters a patient-centered approach to drug development.
Investor Relations and Company Contact
As Apellis Pharmaceuticals continues to grow and evolve, they invite those interested to learn more about their future endeavors and commitments. Investors and stakeholders can reach out to the company for more information:
Investor Contact:
Eva Stroynowski
Email: ir@apellis.com
Phone: 617.938.6229
Frequently Asked Questions
What is the upcoming conference about?
The Stifel 2025 Healthcare Conference is a platform for innovative companies like Apellis Pharmaceuticals to present their advancements and contributions to the healthcare sector.
How can I join the live presentation?
You can access the live presentation through Apellis' official events page dedicated to investors and media.
Will the presentation be available later?
Yes, a replay of the presentation will be available for about 90 days after the live event.
What innovations is Apellis Pharmaceuticals known for?
Apellis is renowned for its work in complement science, particularly developing therapies for geographic atrophy and severe kidney diseases.
How can I contact Apellis Pharmaceuticals?
You can reach the investor relations through the email ir@apellis.com or by phone at 617.938.6229.
